114 related articles for article (PubMed ID: 37497644)
1. The use of deep learning models to predict progression-free survival in patients with neuroendocrine tumors.
Pavel M; Dromain C; Ronot M; Schaefer N; Mandair D; Gueguen D; Elvira D; Jégou S; Balazard F; Dehaene O; Schutte K
Future Oncol; 2023 Oct; 19(32):2185-2199. PubMed ID: 37497644
[No Abstract] [Full Text] [Related]
2. Response heterogeneity as a new biomarker of treatment response in patients with neuroendocrine tumors.
Dromain C; Pavel M; Ronot M; Schaefer N; Mandair D; Gueguen D; Cheng C; Dehaene O; Schutte K; Cahané D; Jégou S; Balazard F
Future Oncol; 2023 Oct; 19(32):2171-2183. PubMed ID: 37497626
[TBL] [Abstract][Full Text] [Related]
3. Survival outcome prediction in cervical cancer: Cox models vs deep-learning model.
Matsuo K; Purushotham S; Jiang B; Mandelbaum RS; Takiuchi T; Liu Y; Roman LD
Am J Obstet Gynecol; 2019 Apr; 220(4):381.e1-381.e14. PubMed ID: 30582927
[TBL] [Abstract][Full Text] [Related]
4. A radiomics-based deep learning approach to predict progression free-survival after tyrosine kinase inhibitor therapy in non-small cell lung cancer.
Lu CF; Liao CY; Chao HS; Chiu HY; Wang TW; Lee Y; Chen JR; Shiao TH; Chen YM; Wu YT
Cancer Imaging; 2023 Jan; 23(1):9. PubMed ID: 36670497
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of anthropometric measures extracted from whole-body CT using deep learning in patients with non-small-cell lung cancer.
Blanc-Durand P; Campedel L; Mule S; Jegou S; Luciani A; Pigneur F; Itti E
Eur Radiol; 2020 Jun; 30(6):3528-3537. PubMed ID: 32055950
[TBL] [Abstract][Full Text] [Related]
6. Machine learning models predict overall survival and progression free survival of non-surgical esophageal cancer patients with chemoradiotherapy based on CT image radiomics signatures.
Cui Y; Li Z; Xiang M; Han D; Yin Y; Ma C
Radiat Oncol; 2022 Dec; 17(1):212. PubMed ID: 36575480
[TBL] [Abstract][Full Text] [Related]
7. Tumor growth rate as a metric of progression, response, and prognosis in pancreatic and intestinal neuroendocrine tumors.
Dromain C; Pavel ME; Ruszniewski P; Langley A; Massien C; Baudin E; Caplin ME;
BMC Cancer; 2019 Jan; 19(1):66. PubMed ID: 30642293
[TBL] [Abstract][Full Text] [Related]
8. Effect of Lanreotide Depot/Autogel on Urinary 5-Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors.
Pavel ME; Phan AT; Wolin EM; Mirakhur B; Liyanage N; Pitman Lowenthal S; Fisher GA; Vinik AI;
Oncologist; 2019 Apr; 24(4):463-474. PubMed ID: 30355775
[TBL] [Abstract][Full Text] [Related]
9. Determination of an optimal response cut-off able to predict progression-free survival in patients with well-differentiated advanced pancreatic neuroendocrine tumours treated with sunitinib: an alternative to the current RECIST-defined response.
Lamarca A; Barriuso J; Kulke M; Borbath I; Lenz HJ; Raoul JL; Meropol NJ; Lombard-Bohas C; Posey J; Faivre S; Raymond E; Valle JW
Br J Cancer; 2018 Jan; 118(2):181-188. PubMed ID: 29161241
[TBL] [Abstract][Full Text] [Related]
10. The role of early ¹⁸F-FDG PET/CT in prediction of progression-free survival after ⁹⁰Y radioembolization: comparison with RECIST and tumour density criteria.
Zerizer I; Al-Nahhas A; Towey D; Tait P; Ariff B; Wasan H; Hatice G; Habib N; Barwick T
Eur J Nucl Med Mol Imaging; 2012 Sep; 39(9):1391-9. PubMed ID: 22644713
[TBL] [Abstract][Full Text] [Related]
11. CT-based radiomics for prediction of therapeutic response to Everolimus in metastatic neuroendocrine tumors.
Caruso D; Polici M; Rinzivillo M; Zerunian M; Nacci I; Marasco M; Magi L; Tarallo M; Gargiulo S; Iannicelli E; Annibale B; Laghi A; Panzuto F
Radiol Med; 2022 Jul; 127(7):691-701. PubMed ID: 35717429
[TBL] [Abstract][Full Text] [Related]
12. Evaluating radiological response in pancreatic neuroendocrine tumours treated with sunitinib: comparison of Choi versus RECIST criteria (CRIPNET_ GETNE1504 study).
Solis-Hernandez MP; Fernandez Del Valle A; Carmona-Bayonas A; Garcia-Carbonero R; Custodio A; Benavent M; Alonso Gordoa T; Nuñez-Valdovino B; Sanchez Canovas M; Matos I; Alonso V; Lopez C; Viudez A; Izquierdo M; Calvo-Temprano D; Grande E; Capdevila J; Jimenez-Fonseca P
Br J Cancer; 2019 Oct; 121(7):537-544. PubMed ID: 31477779
[TBL] [Abstract][Full Text] [Related]
13. Special issue "The advance of solid tumor research in China": Prediction of Sunitinib efficacy using computed tomography in patients with pancreatic neuroendocrine tumors.
Chen L; Wang W; Jin K; Yuan B; Tan H; Sun J; Guo Y; Luo Y; Feng ST; Yu X; Chen MH; Chen J
Int J Cancer; 2023 Jan; 152(1):90-99. PubMed ID: 36111424
[TBL] [Abstract][Full Text] [Related]
14. Deep Learning-based Recalibration of the CUETO and EORTC Prediction Tools for Recurrence and Progression of Non-muscle-invasive Bladder Cancer.
Jobczyk M; Stawiski K; Kaszkowiak M; Rajwa P; Różański W; Soria F; Shariat SF; Fendler W
Eur Urol Oncol; 2022 Feb; 5(1):109-112. PubMed ID: 34092528
[TBL] [Abstract][Full Text] [Related]
15. Preoperative Prediction of Pancreatic Neuroendocrine Neoplasms Grading Based on Enhanced Computed Tomography Imaging: Validation of Deep Learning with a Convolutional Neural Network.
Luo Y; Chen X; Chen J; Song C; Shen J; Xiao H; Chen M; Li ZP; Huang B; Feng ST
Neuroendocrinology; 2020; 110(5):338-350. PubMed ID: 31525737
[TBL] [Abstract][Full Text] [Related]
16. Machine learning-based development and validation of a scoring system for progression-free survival in liver cancer.
Liu X; Hou Y; Wang X; Yu L; Wang X; Jiang L; Yang Z
Hepatol Int; 2020 Jul; 14(4):567-576. PubMed ID: 32556865
[TBL] [Abstract][Full Text] [Related]
17. Prognostic Factors Associated With Progression for Advanced-Stage/G1 and G2 Small-Bowel Neuroendocrine Tumors After Multimodal Therapy: Experience From a Tertiary Referral Center.
Khetan P; Oyewole F; Wolin E; Kim MK; Divino CM
Pancreas; 2020 Apr; 49(4):509-513. PubMed ID: 32224719
[TBL] [Abstract][Full Text] [Related]
18. Establishing the Quantitative Relationship Between Lanreotide Autogel®, Chromogranin A, and Progression-Free Survival in Patients with Nonfunctioning Gastroenteropancreatic Neuroendocrine Tumors.
Buil-Bruna N; Dehez M; Manon A; Nguyen TX; Trocóniz IF
AAPS J; 2016 May; 18(3):703-12. PubMed ID: 26908127
[TBL] [Abstract][Full Text] [Related]
19. The value of serum chromogranin A as a predictor of tumor burden, therapeutic response, and nomogram-based survival in well-moderate nonfunctional pancreatic neuroendocrine tumors with liver metastases.
Han X; Zhang C; Tang M; Xu X; Liu L; Ji Y; Pan B; Lou W
Eur J Gastroenterol Hepatol; 2015 May; 27(5):527-35. PubMed ID: 25822862
[TBL] [Abstract][Full Text] [Related]
20.
Carlsen EA; Johnbeck CB; Binderup T; Loft M; Pfeifer A; Mortensen J; Oturai P; Loft A; Berthelsen AK; Langer SW; Knigge U; Kjaer A
J Nucl Med; 2020 Oct; 61(10):1491-1497. PubMed ID: 32111685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
